Clinical Trials | June 03, 2026
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Subscribe To Our Newsletter & Stay Updated
